var data={"title":"Rabeprazole: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Rabeprazole: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6889?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=rabeprazole-patient-drug-information\" class=\"drug drug_patient\">see &quot;Rabeprazole: Patient drug information&quot;</a> and <a href=\"topic.htm?path=rabeprazole-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Rabeprazole: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50836902\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Proton Pump Inhibitors Safety Alert</span>\n      <span class=\"collapsible-date\">December 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Health Canada has issued a safety alert regarding the rare risk of subacute cutaneous lupus erythematosus with the use of proton pump inhibitors (PPI). This alert was prompted following a published article that examined reports in the FDA Adverse Event Reporting System.</p>\n        <p style=\"text-indent:0em;\">Health Canada is working with manufacturers to update the safety information to include these findings in all PPI-containing products. More information may be found at https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/proton-pump-inhibitors-assessing-risk-type-skin-reaction.html.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10539946\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Aciphex;</li>\n      <li>AcipHex Sprinkle</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216709\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Rabeprazole;</li>\n      <li>Pariet;</li>\n      <li>Pat-Rabeprazole;</li>\n      <li>PMS-Rabeprazole EC;</li>\n      <li>PRO-Rabeprazole;</li>\n      <li>Rabeprazole EC;</li>\n      <li>RAN-Rabeprazole;</li>\n      <li>Riva-Rabeprazole EC;</li>\n      <li>Sandoz-Rabeprazole;</li>\n      <li>Teva-Rabeprazole EC</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216743\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Proton Pump Inhibitor;</li>\n      <li>\n        Substituted Benzimidazole</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216713\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Duodenal ulcer:</b> Tablets: Oral: 20 mg once daily for &le;4 weeks; additional therapy to achieve healing may be required for some patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gastric ulcers:</b> <i>Canadian labeling: </i>Tablets: Oral: 20 mg once daily up to 6 weeks; additional therapy to achieve healing may be required for some patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gastroesophageal reflux disease (GERD):</b> Tablets: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Erosive or ulcerative GERD: </i>Treatment: 20 mg once daily for 4 to 8 weeks; if inadequate response, may repeat up to an additional 8 weeks; maintenance: 20 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Symptomatic GERD: </i>Treatment: 20 mg once daily for &le;4 weeks; if inadequate response, may repeat for an additional 4 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Helicobacter pylori</i> eradication:</b> Tablets: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer labeling: 20 mg twice daily administered with amoxicillin 1,000 mg <i>and</i> clarithromycin 500 mg twice daily for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">American College of Gastroenterology guidelines (ACG [Chey 2007; Chey 2017]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Clarithromycin triple regimen: </i>20 to 40 mg twice daily in combination with clarithromycin 500 mg twice daily and either amoxicillin 1 g twice daily or metronidazole 500 mg 3 times per day; continue regimen for 14 days.<b> Note:</b> Avoid use of clarithromycin triple therapy in patients with risk factors for macrolide resistance (eg, prior macrolide exposure, local clarithromycin resistance rates &ge;15%, eradication rates with clarithromycin-based regimens &le;85%) (ACG [Chey 2017]; Fallone 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Bismuth quadruple regimen:</i> 20 mg twice daily in combination with tetracycline 500 mg 4 times per day, metronidazole 250 mg 4 times per day or 500 mg 3 or 4 times per day, and either bismuth subcitrate 120 to 300 mg 4 times per day or bismuth subsalicylate 300 mg 4 times per day; continue regimen for 10 to 14 days.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Concomitant regimen: </i>20 mg twice daily in combination with amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and either metronidazole or tinidazole 500 mg twice daily; continue regimen for 10 to 14 days.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Sequential regimen: </i>20 mg twice daily plus amoxicillin 1 g twice daily for 5 to 7 days; then continue rabeprazole along with clarithromycin 500 mg twice daily, and either metronidazole or tinidazole 500 mg twice daily for 5 to 7 days.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Hybrid regimen: </i>20 mg twice daily plus amoxicillin 1 g twice daily for 7 days; then continue rabeprazole and amoxicillin along with clarithromycin 500 mg twice daily, and either metronidazole or tinidazole 500 mg twice daily for 7 days.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Levofloxacin triple regimen:</i> 20 mg twice daily in combination with amoxicillin 1 g twice daily and levofloxacin 500 mg once daily; continue regimen for 10 to 14 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypersecretory conditions (including Zollinger-Ellison Syndrome): </b>Tablets: Oral: Initial: 60 mg once daily; adjust dose to patient needs (some may require divided doses). Doses as high as 100 mg once daily and 60 mg twice daily have been used; continue as long as clinically indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nonerosive reflux disease (NERD): </b> <i>Canadian labeling: </i>Tablets: Oral: Treatment: 10 mg (maximum: 20 mg once daily) for 4 weeks; lack of symptom control after 4 weeks warrants further evaluation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6189304\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=rabeprazole-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Rabeprazole: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gastroesophageal reflux disease (GERD), symptomatic:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 1 to 11 years: Capsules: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;15 kg: 5 mg once daily for &le;12 weeks; if inadequate response may increase to 10 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;15 kg: 10 mg once daily for &le;12 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;12 years and Adolescents: Oral: Tablets: 20 mg once daily for &le;8 weeks.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216714\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216715\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216716\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Mild-to-moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Severe impairment (Child-Pugh class C): Avoid use; if treatment is necessary, monitor for adverse reactions. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216683\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Sprinkle, Oral, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AcipHex Sprinkle: 5 mg [contains fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AcipHex Sprinkle: 10 mg [contains fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Delayed Release, Oral, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aciphex: 20 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216669\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5940143\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Sprinkle capsules are not available in Canada</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, delayed release, enteric coated, as sodium:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pariet: 10 mg, 20 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15386957\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Aciphex DR: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM497380.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/8bxp4YrxUVJFUAWh6274gimMXp4hlnOf/MHd5lGUoUPg==&amp;TOPIC_ID=9519\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM497380.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Aciphex Sprinkle: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204736s008lbl.pdf#page=20&amp;token=x8SJzREsvMcxvuQtpWBWUtB+wytSAxwUJZIbbZgi8cJE1EANv8yCxpcHuuYJEVLHCOgLqlapVP9Ff+6Pg89+6wro5pREr2s1YVHMWq54kbvQsmLbli+7I0hwFv7dHcKu&amp;TOPIC_ID=9519\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204736s008lbl.pdf#page=20</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216686\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">May be administered with an antacid.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Capsules: Administer 30 minutes before a meal.  Open capsule and sprinkle entire contents on a small amount of soft food (eg, applesauce, fruit or vegetable based baby food, yogurt) or empty contents into a small amount of liquid (eg, infant formula, apple juice, pediatric electrolyte solution); food or liquid should be at or below room temperature. Do not swallow capsule whole, or chew or crush granules; administer whole dose within 15 minutes of preparation (do not store for future use).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablets: Swallow whole; do not crush, split, or chew; may administer with or without food. However, when used for the treatment of duodenal ulcers, administer after a meal; when used for the eradication of <i>H. pylori</i>, administer with the morning and evening meals. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216685\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Duodenal ulcers (tablets only):</b> Short-term (4 weeks or fewer) treatment in the healing and symptomatic relief of duodenal ulcers in adults.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gastroesophageal reflux disease:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Erosive or ulcerative (tablets only): </i>Short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (GERD) in adults; for maintaining healing and reduction in relapse rates of heartburn symptoms in adults with erosive or ulcerative GERD.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Symptomatic: </i>Treatment of symptomatic GERD for up to 4 weeks in adults (tablets only), up to 8 weeks in children &ge;12 years and adolescents (tablets only), and up to 12 weeks in children 1 to 11 years of age (capsules only).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Helicobacter pylori</i> eradication (tablets only): </b> In combination with amoxicillin and clarithromycin as a 3-drug regimen for the treatment of adults with <i>H. pylori</i> infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate <i>H. pylori</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pathological hypersecretory conditions (tablets only):</b> Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Canadian labeling:</i> Additional uses (not in US labeling): Treatment of nonerosive reflux disease (NERD); treatment of gastric ulcers</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25744899\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Stress ulcer prophylaxis in critically-ill patients; Duodenal ulcer (maintenance of healing/prevention of relapse); NSAID-induced ulcer (treatment/prevention)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216750\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">AcipHex may be confused with Acephen, Accupril, Aricept, pHisoHex</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">RABEprazole may be confused with ARIPiprazole, donepezil, lansoprazole, omeprazole, raloxifene</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Proton pump inhibitors are identified in the Beers Criteria as potentially inappropriate medications to be avoided (as scheduled use for more than 8 weeks) in patients 65 years and older due to its risk of <i>C. difficile</i> infection and bone loss/fractures. Use more than 8 weeks should be avoided <i>unless</i> given for high-risk patients (eg, oral corticosteroid or chronic NSAID use), patients with erosive esophagitis, Barrett's esophagitis, a pathological hypersecretory condition, or if the patient has demonstrated a need for maintenance therapy (eg, failure of drug discontinuation trial or failure of H2 blockers) (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216676\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Gastrointestinal: Diarrhea (children and adolescents: 5% to 21%; adults: &lt;2%), abdominal pain (children: 16%; adolescents and adults: &le;4%), vomiting (children: 10% to 14%; adolescents: 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema (adults: &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (children and adolescents: 5% to 10% adults: &lt;2%), pain (adults: 3%), dizziness (adults: &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (children and adolescents: 2% to 9%), flatulence (adults: 3%), constipation (adults: 2%), xerostomia (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Hepatic encephalopathy (adults: &lt;2%), hepatitis (adults: &lt;2%), increased liver enzymes (adults: &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (adults: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (adults: &lt;2%), myalgia (adults: &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pharyngitis (adults: 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Agranulocytosis, anaphylaxis, angioedema, blurred vision, bone fracture, bullous rash, <i>Clostridium difficile</i> associated diarrhea, coma, cutaneous lupus erythematous, delirium, disorientation, erythema multiforme, hemolytic anemia, hepatotoxicity (idiosyncratic) (Chalasani 2014), hyperammonemia, hypomagnesemia, increased thyroid stimulating hormone level, interstitial nephritis, jaundice, leukopenia, pancytopenia, pneumonia (interstitial), renal disease (chronic; Lazarus 2016), rhabdomyolysis, Stevens-Johnson syndrome, systemic lupus erythematosus, thrombocytopenia, toxic epidermal necrolysis, vertigo</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216689\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity (eg, anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute interstitial nephritis, urticaria) to rabeprazole, other substituted benzimidazoles, or any component of the formulation; concomitant use with rilpivirine-containing products</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216673\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Atrophic gastritis: Long-term omeprazole therapy has caused atrophic gastritis (by biopsy); this may also occur with rabeprazole.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Carcinoma: No reports of adenomatoid, dysplastic or neoplastic changes of enterochromaffin-like (ECL) cells in the gastric mucosa have occurred.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; <i>Clostridium difficile</i>-associated diarrhea (CDAD): Use of proton pump inhibitors (PPIs) may increase risk of CDAD, especially in hospitalized patients; consider CDAD diagnosis in patients with persistent diarrhea that does not improve. Use the lowest dose and shortest duration of PPI therapy appropriate for the condition being treated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cutaneous and systemic lupus erythematosus: Has been reported as new onset or exacerbation of existing autoimmune disease; most cases were cutaneous lupus erythematosus (CLE), most commonly, subacute CLE (occurring within weeks to years after continuous therapy). Systemic lupus erythematosus (SLE) is less common (typically occurs within days to years after initiating treatment) and occurred primarily in young adults up to the elderly. Discontinue therapy if signs or symptoms of CLE or SLE occur and refer to specialist for evaluation; most patients improve 4 to 12 weeks after discontinuation of rabeprazole.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fractures: Increased incidence of osteoporosis-related bone fractures of the hip, spine, or wrist may occur with proton pump inhibitor (PPI) therapy. Patients on high-dose (multiple daily doses) or long-term therapy (&ge;1 year) should be monitored. Use the lowest effective dose for the shortest duration of time, use vitamin D and calcium supplementation, and follow appropriate guidelines to reduce risk of fractures in patients at risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal infection (eg, <i>Salmonella</i>, <i>Campylobacter</i>): Use of proton pump inhibitors may increase risk of these infections.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypomagnesemia: Reported rarely, usually with prolonged PPI use of &ge;3 months (most cases &gt;1 year of therapy). May be symptomatic or asymptomatic; severe cases may cause tetany, seizures, and cardiac arrhythmias. Consider obtaining serum magnesium concentrations prior to beginning long-term therapy, especially if taking concomitant digoxin, diuretics, or other drugs known to cause hypomagnesemia; and periodically thereafter. Hypomagnesemia may be corrected by magnesium supplementation, although discontinuation of rabeprazole may be necessary; magnesium levels typically return to normal within 1 week of stopping.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Interstitial nephritis: Acute interstitial nephritis has been observed in patients taking PPIs; may occur at any time during therapy and is generally due to an idiopathic hypersensitivity reaction. Discontinue if acute interstitial nephritis develops.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vitamin B<sub>12</sub> deficiency: Prolonged treatment (&gt;3 years) may lead to vitamin B<sub>12</sub> malabsorption and subsequent vitamin B<sub>12</sub> deficiency. The magnitude of the deficiency is dose-related and the association is stronger in females and those younger in age (&lt;30 years); prevalence is decreased after discontinuation of therapy (Lam 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastric malignancy: Relief of symptoms does not preclude the presence of a gastric malignancy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Avoid use in patients with severe hepatic impairment; if treatment is necessary monitor for adverse reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends either avoidance of both omeprazole (even when scheduled 12 hours apart) and esomeprazole or use of a PPI with comparatively less effect on the active metabolite of clopidogrel. Avoidance of rabeprazole appears prudent due to potent <i>in vitro</i> CYP2C19 inhibition (Li 2004) and lack of sufficient comparative <i>in vivo</i> studies with other PPIs. In contrast to these warnings, others have recommended the continued use of PPIs, regardless of the degree of inhibition, in patients with a history of GI bleeding or multiple risk factors for GI bleeding who are also receiving clopidogrel since no evidence has established clinically meaningful differences in outcome; however, a clinically-significant interaction cannot be excluded in those who are poor metabolizers of clopidogrel (Abraham 2010; Levine 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: <i>Helicobacter pylori</i> eradication: Short-term combination therapy (&le;7 days) has been associated with a higher incidence of treatment failure. The American College of Gastroenterology recommends 10 to 14 days of therapy (triple or quadruple) for eradication of <i>H. pylori</i> (Chey 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216736\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2C19 (major), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216678\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9519&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acalabrutinib: Proton Pump Inhibitors may decrease the serum concentration of Acalabrutinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamine: Proton Pump Inhibitors may increase the absorption of Amphetamine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atazanavir: Proton Pump Inhibitors may decrease the serum concentration of Atazanavir.  Management: See full drug interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Proton Pump Inhibitors may diminish the therapeutic effect of Bisphosphonate Derivatives. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosutinib: Proton Pump Inhibitors may decrease the serum concentration of Bosutinib.  Management: Consider alternatives to proton pump inhibitors, such as antacids or H2 receptor antagonists.  Administer alternative agents more than 2 hours before or after bosutinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capecitabine: Proton Pump Inhibitors may diminish the therapeutic effect of Capecitabine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefditoren: Proton Pump Inhibitors may decrease the serum concentration of Cefditoren.  Management: If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefpodoxime: Proton Pump Inhibitors may decrease the serum concentration of Cefpodoxime. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefuroxime: Proton Pump Inhibitors may decrease the absorption of Cefuroxime. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clopidogrel: RABEprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel.  Management: Due to the possible risk for impaired clopidogrel effectiveness, clinicians should carefully consider the need for proton pump inhibitor therapy in patients receiving clopidogrel.  Other acid-lowering therapies do not appear to share this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cysteamine (Systemic): Proton Pump Inhibitors may diminish the therapeutic effect of Cysteamine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Dabigatran Etexilate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP2C19 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP2C19 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: Proton Pump Inhibitors may decrease the serum concentration of Dabrafenib. Dabrafenib may decrease the serum concentration of Proton Pump Inhibitors.  Management: Seek alternatives to the proton pump inhibitor when possible.  If concomitant therapy cannot be avoided, monitor for diminished effects of both drugs.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: Proton Pump Inhibitors may decrease the serum concentration of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of the proton pump inhibitor if some acid-reducing therapy is needed.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Delavirdine: Proton Pump Inhibitors may decrease the serum concentration of Delavirdine.  Management: Chronic therapy with proton pump inhibitors (PPIs) should be avoided in patients treated with delavirdine.  The clinical significance of short-term PPI therapy with delavirdine is uncertain, but such therapy should be undertaken with caution.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexmethylphenidate: Proton Pump Inhibitors may increase the absorption of Dexmethylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dextroamphetamine: Proton Pump Inhibitors may increase the absorption of Dextroamphetamine. Specifically, the dextroamphetamine absorption rate from mixed amphetamine salt extended release (XR) capsules may be increased in the first hours after dosing. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP2C19 Substrates (High risk with Inducers). Conversely, concentrations of active metabolites may be increased for those drugs activated by CYP2C19. Management: Concurrent use of enzalutamide with CYP2C19 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP2C19 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erlotinib: Proton Pump Inhibitors may decrease the serum concentration of Erlotinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: May increase the serum concentration of Proton Pump Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gefitinib: Proton Pump Inhibitors may decrease the serum concentration of Gefitinib.  Management: Avoid use of proton pump inhibitors (PPIs) with gefitinib when possible. If required, administer gefitinib 12 hours after administration of the PPI or 12 hours before the next dose of the PPI.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indinavir: Proton Pump Inhibitors may decrease the serum concentration of Indinavir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: Proton Pump Inhibitors may decrease the absorption of Iron Salts. <b> Exceptions: </b>Ferric Carboxymaltose; Ferric Citrate; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: Proton Pump Inhibitors may decrease the serum concentration of Itraconazole. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoconazole (Systemic): Proton Pump Inhibitors may decrease the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Proton Pump Inhibitors. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ledipasvir: Proton Pump Inhibitors may decrease the serum concentration of Ledipasvir.  Management: PPI doses equivalent to omeprazole 20 mg or lower may be given with ledipasvir under fasted conditions. Administration with higher doses of PPIs, 2 hours after a PPI, or in combination with food and PPIs may reduce ledipasvir bioavailability.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mesalamine: Proton Pump Inhibitors may diminish the therapeutic effect of Mesalamine. Proton pump inhibitor-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Consider avoiding concurrent administration of high-dose proton pump inhibitors (PPIs) with sustained-release mesalamine products.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Proton Pump Inhibitors may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: Proton Pump Inhibitors may increase the absorption of Methylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): Proton Pump Inhibitors may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, the absorption of iron may be decreased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Proton Pump Inhibitors may decrease the serum concentration of Mycophenolate. Specifically, concentrations of the active mycophenolic acid may be reduced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nelfinavir: Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Nelfinavir. Proton Pump Inhibitors may decrease the serum concentration of Nelfinavir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neratinib: Proton Pump Inhibitors may decrease the serum concentration of Neratinib. Specifically, proton pump inhibitors may reduce neratinib absorption. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nilotinib: Proton Pump Inhibitors may decrease the serum concentration of Nilotinib.  Management: Avoid this combination when possible since separation of doses is not likely to be an adequate method of minimizing the interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PAZOPanib: Proton Pump Inhibitors may decrease the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Posaconazole: Proton Pump Inhibitors may decrease the serum concentration of Posaconazole. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Raltegravir: Proton Pump Inhibitors may increase the serum concentration of Raltegravir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilpivirine: Proton Pump Inhibitors may decrease the serum concentration of Rilpivirine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Riociguat: Proton Pump Inhibitors may decrease the serum concentration of Riociguat. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Risedronate: Proton Pump Inhibitors may diminish the therapeutic effect of Risedronate. Proton Pump Inhibitors may increase the serum concentration of Risedronate. This applies specifically to use of delayed-release risedronate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saquinavir: Proton Pump Inhibitors may increase the serum concentration of Saquinavir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Secretin: Proton Pump Inhibitors may diminish the diagnostic effect of Secretin. Specifically, use of PPIs may cause a hyperresponse in gastrin secretion in response to secretin stimulation testing, falsely suggesting gastrinoma.  Management: Avoid concomitant use of proton pump inhibitors (PPIs) and secretin, and discontinue PPIs several weeks prior to secretin administration, with the duration of separation determined by the specific PPI. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Proton Pump Inhibitors may increase the serum concentration of Tacrolimus (Systemic).  Management: Tacrolimus dose adjustment may be required. Rabeprazole, pantoprazole, or selected H2-receptor antagonists (i.e., ranitidine or famotidine) may be less likely to interact. Genetic testing may predict patients at highest risk.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May decrease the serum concentration of Proton Pump Inhibitors. These data are derived from studies with Ritonavir-boosted Tipranavir.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Velpatasvir: Proton Pump Inhibitors may decrease the serum concentration of Velpatasvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: May increase the serum concentration of Proton Pump Inhibitors. Proton Pump Inhibitors may increase the serum concentration of Voriconazole. Management: In patients receiving omeprazole 40 mg/day or greater, reduce omeprazole dose by half when initiating voriconazole.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216705\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Prolonged treatment (&ge;2 years) may lead to malabsorption of dietary vitamin B<sub>12</sub> and subsequent vitamin B<sub>12</sub> deficiency (Lam, 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216691\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Available studies have not shown an increased risk of major birth defects following maternal use of proton pump inhibitors during pregnancy; however, information specific to rabeprazole is limited (Pasternak 2010); most information available for omeprazole. When treating GERD in pregnancy, PPIs may be used when clinically indicated (Katz 2013). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20232738\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if rabeprazole is present in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216692\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Capsules: Take 30 minutes before a meal.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablets: When used for the treatment of duodenal ulcers, administer after a meal; when used for the eradication of <i>Helicobacter pylori</i>, administer with the morning and evening meals. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22688298\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Magnesium levels (prior to initiation of therapy and periodically thereafter) in patients on long-term treatment or those taking digoxin, diuretics, or other drugs that cause hypomagnesemia; susceptibility testing recommended in patients who fail <i>H. pylori</i> eradication regimen.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216672\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Potent proton pump inhibitor; suppresses gastric acid secretion by inhibiting the parietal cell H+/K+ ATP pump</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216688\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Within 1 hour </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: 24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Well absorbed within 1 hour; food delayed absorption up to 4 hours or longer</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 96.3% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic via CYP3A and 2C19 to inactive metabolites; CYP2C19 exhibits a known genetic polymorphism due to its deficiency in some subpopulations (3% to 5% of Caucasians and 17% to 20% of Asians) which results in slower metabolism  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Tablet: ~52% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination (dose dependent): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adolescents: ~0.55 to 1 hour (James 2007) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 1 to 2 hours; two- to threefold higher in patients with mild-to-moderate hepatic impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adolescents: Tablet: 3.3 to 4.1 hours (James 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Tablet: 2 to 5 hours; Capsule: 1 to 6.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (90% primarily as thioether carboxylic acid metabolites); remainder in feces</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2524721\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, sprinkles</b> (AcipHex Sprinkle Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (30): $617.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $658.67</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Aciphex Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (30): $629.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (RABEprazole Sodium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (30): $343.43</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216693\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acifix (BD);</li>\n      <li>Acilesol (SG);</li>\n      <li>Aciprazol (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Ares (HR);</li>\n      <li>Barole (PH);</li>\n      <li>Gastrodine (CL);</li>\n      <li>Gelbra (ES);</li>\n      <li>Happi (LK);</li>\n      <li>Noflux (CZ);</li>\n      <li>Paliell (KR);</li>\n      <li>Paramet (KR);</li>\n      <li>Paricel (BD);</li>\n      <li>Pariet (AE, AR, AT, AU, BB, BE, BG, BH, BM, BO, BR, BS, CH, CN, CO, CR, CY, DE, DK, DO, EG, ES, FI, FR, GB, GR, GT, GY, HK, HN, ID, IE, IL, IQ, IR, IS, IT, JM, JO, JP, KR, KW, LB, LT, LU, LY, MT, MX, MY, NI, NL, NZ, OM, PA, PE, PH, PL, PR, PT, PY, QA, RU, SA, SE, SG, SR, SV, SY, TH, TR, TT, TW, UY, VE, VN, YE, ZA, ZW);</li>\n      <li>Pariyet (UA);</li>\n      <li>Promto (VN);</li>\n      <li>Rabe (BD, LK);</li>\n      <li>Rabeact (LK);</li>\n      <li>Rabeact-20 (HK);</li>\n      <li>Rabec (AR, LB);</li>\n      <li>Rabecid (PK);</li>\n      <li>Rabegen (KR);</li>\n      <li>Rabekind (TZ);</li>\n      <li>Rabeloc (IN, VN);</li>\n      <li>Rabelok (UA);</li>\n      <li>Rabeol (KR);</li>\n      <li>Raberin (KR);</li>\n      <li>Rabesta (KR, PH);</li>\n      <li>Rabestad (HK);</li>\n      <li>Rabet (KR);</li>\n      <li>Rabetra (HK);</li>\n      <li>Rabezole (QA, SA);</li>\n      <li>Rabiet (KR);</li>\n      <li>Rabister (KR);</li>\n      <li>Rabium (BD);</li>\n      <li>Rapeed (PH);</li>\n      <li>Rapoxol (CZ);</li>\n      <li>Rasonix (BD);</li>\n      <li>Razole (IE);</li>\n      <li>Rebacip (LB);</li>\n      <li>Relitaz (RO);</li>\n      <li>Renom (LK);</li>\n      <li>Risol (LK);</li>\n      <li>Veloz (ZW);</li>\n      <li>Zulbeks (UA);</li>\n      <li>Zulbex (CZ, HR, LV, RO)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abraham NS, Hlatky MA, Antman EM, et al, &ldquo;ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents,&rdquo; <i>Circulation</i>, 2010, 122(24):2619-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rabeprazole-drug-information/abstract-text/21060077/pubmed\" target=\"_blank\" id=\"21060077\">21060077</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    AcipHex (rabeprazole) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    AcipHex (rabeprazole) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aciphex Sprinkle (rabeprazole) [prescribing information]. Research Triangle Park, NC: Cerecor Inc; January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc.</i> 2015;63(11):2227-2246. doi:10.1111/jgs.13702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rabeprazole-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bell AD, Roussin A, Cartier R, et al, &ldquo;The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines,&rdquo; <i>Can J Cardiol</i>, 2011, 27(Suppl A):1-59.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rabeprazole-drug-information/abstract-text/21640290/pubmed\" target=\"_blank\" id=\"21640290\">21640290</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rabeprazole-drug-information/abstract-text/24935270/pubmed\" target=\"_blank\" id=\"24935270\">24935270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28071659\"></a>Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. <i>Am J Gastroenterol</i>. 2017;112(2):212-239. doi: 10.1038/ajg.2016.563.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rabeprazole-drug-information/abstract-text/28071659/pubmed\" target=\"_blank\" id=\"28071659\">28071659</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chey WD, Wong BC; Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of <i>Helicobacter pylori</i> infection. <i>Am J Gastroenterol</i>. 2007;102(8):1808-1825. doi: 10.1111/j.1572-0241.2007.01393.x.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rabeprazole-drug-information/abstract-text/17608775/pubmed\" target=\"_blank\" id=\"17608775\">17608775</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cockayne SE, Glet RJ, Gawkrodger DJ, et al, &ldquo;Severe Erythrodermic Reactions to the Proton Pump Inhibitors Omeprazole and Lansoprazole,&rdquo; <i>Br J Dermatol</i>,1999, 141(1):173-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rabeprazole-drug-information/abstract-text/10417548/pubmed\" target=\"_blank\" id=\"10417548\">10417548</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Jager CP, Wever PC, Gemen EF, et al, &ldquo;Proton Pump Inhibitor Therapy Predisposes to Community-Acquired <i>Streptococcus pneumoniae</i> Pneumonia,&rdquo; <i>Aliment Pharmacol Ther</i>, 2012, 36(10):941-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rabeprazole-drug-information/abstract-text/23034135/pubmed\" target=\"_blank\" id=\"23034135\">23034135</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of <i>Helicobacter pylori</i> infection in adults. <i>Gastroenterology.</i> 2016;151(1):51-69.e14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rabeprazole-drug-information/abstract-text/27102658/pubmed\" target=\"_blank\" id=\"27102658\">27102658</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    James L, Walson P, Lomax K, et al. Pharmacokinetics and tolerability of rabeprazole sodium in subjects aged 12 to 16 years with gastroesophageal reflux disease: an open-label, single- and multiple-dose study. <i>Clin Ther</i>. 2007; 29(9):2082-2092.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rabeprazole-drug-information/abstract-text/18035206/pubmed\" target=\"_blank\" id=\"18035206\">18035206</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kahrilas PJ, Shaheen NJ, Vaezi MF, et al, &ldquo;American Gastroenterological Association Medical Position Statement on the Management of Gastroesophageal Reflux Disease,&rdquo; <i>Gastroenterology</i>, 2008, 135(4):1383-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rabeprazole-drug-information/abstract-text/18789939/pubmed\" target=\"_blank\" id=\"18789939\">18789939</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Katz PO, Gerson LB, and Vela MF, &quot;Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease,&quot; <i>Am J Gastroenterol</i>, 2013, 108(3):308-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rabeprazole-drug-information/abstract-text/23419381/pubmed\" target=\"_blank\" id=\"23419381\">23419381</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. <i>JAMA</i>. 2013;310(22):2435-2422.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rabeprazole-drug-information/abstract-text/24327038/pubmed\" target=\"_blank\" id=\"24327038\">24327038</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lanza FL, Chan FK, and Quigley EM, &ldquo;Guidelines for Prevention of NSAID-Related Ulcer Complications,&rdquo; <i>Am J Gastroenterol</i>, 2009, 140(3):728-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rabeprazole-drug-information/abstract-text/19240698/pubmed\" target=\"_blank\" id=\"19240698\">19240698</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. <i>JAMA Intern Med</i>. 2016:238-246.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo; <i>Circulation</i>, 2011, 124(23):e574-651.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rabeprazole-drug-information/abstract-text/22064601/pubmed\" target=\"_blank\" id=\"22064601\">22064601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li X-Q, Anderson TB, Ahlstrom M, et al, &ldquo;Comparison of Inhibitory Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole on Human Cytochrome P450 Activities,&rdquo; <i>Drug Metab Disp</i>, 2004, 32(8):821-7.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moayyedi PM, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N. ACG and CAG clinical guideline: management of dyspepsia. <i>Am J Gastroenterol</i>. 2017;112(7):988-1013. doi: 10.1038/ajg.2017.154.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rabeprazole-drug-information/abstract-text/28631728/pubmed\" target=\"_blank\" id=\"28631728\">28631728</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Natsch S, Vinks MH, Voogt AK, et al, &ldquo;Anaphylactic Reactions to Proton-Pump Inhibitors,&rdquo; <i>Ann Pharmacother</i>, 2000, 34(4):474-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rabeprazole-drug-information/abstract-text/10772433/pubmed\" target=\"_blank\" id=\"10772433\">10772433</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Paoluzi P, Iacopini F, Crispino P, et al, &ldquo;2-Week Triple Therapy for <i>Helicobacter pylori</i> Infection is Better Than 1-Week in Clinical Practice: a Large Prospective Single-Center Randomized Study,&rdquo; <i>Helicobacter</i>, 2006, 11(6):562-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rabeprazole-drug-information/abstract-text/17083378/pubmed\" target=\"_blank\" id=\"17083378\">17083378</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pariet (rabeprazole sodium) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pasternak B and Hviid A, &quot;Use of Proton-Pump Inhibitors in Early Pregnancy and the Risk of Birth Defects,&quot; <i>N Engl J Med</i>, 2010, 363(22):2114-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rabeprazole-drug-information/abstract-text/21105793/pubmed\" target=\"_blank\" id=\"21105793\">21105793</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28101605\"></a>Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. <i>Intensive Care Med</i>. 2017;43(3):304-377.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rabeprazole-drug-information/abstract-text/28101605/pubmed\" target=\"_blank\" id=\"28101605\">28101605</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Talley NJ and Vakil N, &ldquo;Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the Management of Dyspepsia,&rdquo; <i>Am J Gastroenterol</i>, 2005, 100(10):2324-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rabeprazole-drug-information/abstract-text/16181387/pubmed\" target=\"_blank\" id=\"16181387\">16181387</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wolfe MM and Sachs G, &ldquo;Acid Suppression: Optimizing Therapy for Gastroduodenal Ulcer Healing, Gastroesophageal Reflux Disease, and Stress-Related Erosive Syndrome,&rdquo; <i>Gastroenterology</i>, 2000,118(2 Suppl 1):9-31.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9519 Version 227.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50836902\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F10539946\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F216709\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F216743\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F216713\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F6189304\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F216714\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F216715\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F216716\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F216683\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F216669\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F5940143\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F15386957\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F216686\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F216685\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25744899\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F216750\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F216676\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F216689\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F216673\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F216736\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F216678\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F216705\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F216691\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20232738\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F216692\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F22688298\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F216672\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F216688\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F2524721\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F216693\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9519|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=rabeprazole-patient-drug-information\" class=\"drug drug_patient\">Rabeprazole: Patient drug information</a></li><li><a href=\"topic.htm?path=rabeprazole-pediatric-drug-information\" class=\"drug drug_pediatric\">Rabeprazole: Pediatric drug information</a></li></ul></div></div>","javascript":null}